O-13 Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUS

César Serrano; Michael C. Heinrich; Suzanne George; John Zalcberg; Sebastian Bauer; Hans Gelderblom; Patrick Schöffski; Robin L. Jones; Steven Attia; Gina Z. D’Amato; Ping Chi; Peter Reichardt; J. Meade; V. Reichert; Kelvin Shi; Jean Yves Blay; Margaret von Mehren

doi:10.1016/j.annonc.2020.04.066

Related publications

Article2020

Quality of life (QoL) and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.

Michael C. Heinrich, Suzanne George, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, C Pardo Serrano, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Claus Becker, Julie Nicole Meade, Rodrigo Ruiz‐Soto, Margaret von Mehren, Jean Yves Blay

Article2021

1540P Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study

Margaret von Mehren, Michael C. Heinrich, Suzanne George, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, César Serrano, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Julie Nicole Meade, V. Reichert, Kelvin Shi, Rodrigo Ruiz‐Soto, Jean Yves Blay

Article2020

1622MO Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study

John Zalcberg, Michael C. Heinrich, Suzanne George, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, César Serrano, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Julie Nicole Meade, V. Reichert, Kelvin Shi, Rodrigo Ruiz‐Soto, Margaret von Mehren, Jean Yves Blay

Article2020

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

Jean Yves Blay, César Serrano, Michael C. Heinrich, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Julie Meade, Kelvin Shi, Rodrigo Ruiz‐Soto, Suzanne George, Margaret von Mehren

Article2021

Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.

John Zalcberg, Michael C. Heinrich, Suzanne George, Sebastian Bauer, Patrick Schöffski, César Serrano, Robin L. Jones, Hans Gelderblom, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Neeta Somaiah, Julie Nicole Meade, V. Reichert, Kelvin Shi, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Margaret von Mehren, Jean Yves Blay

O-13 Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUS

Discussion(0)

Related publications

Quality of life (QoL) and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.

1540P Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study

1622MO Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.